Home | Welcome to Contract Pharma   
Last Updated Thursday, October 30 2014
Print

Search Results for 'Financial Report: Merck'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published October 28, 2014
Merck 3Q Revenues: $10.6 billion  (-4%) 3Q Earnings: $842 million (-27%) YTD Revenues: $31.8 billion (-3%) YTD Earnings: $4.6 billion (+24%) Comments: Pharmaceutical sales were $9.1 billion in the quarter, down 4%. JANUVIA/JANUMET sales wer… Read More »
Published July 30, 2014
Second quarter profits more than doubled, while sales decreased by 1% Read More »
Published April 29, 2014
Revenues down 4% in the quarter Read More »
By Gil Roth
Published February 5, 2014
Singulair, other patent expirations weigh on revenues Read More »
By Gil Roth
Published July 30, 2013
Singulair generics, strong dollar drag down revenues Read More »
Published February 1, 2013
Revenues down 5% in the quarter Read More »
Published October 26, 2012
Key products help offset August Singulair patent expiry Read More »
Published July 27, 2012
Pharma sales up 2%, hurt by Remicade settlement Read More »
Published April 21, 2009
Worldwide sales of Singulair were $1.1 billion (-4%). Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $945 million (-23%). Read More »
Published April 20, 2006
Merck 1Q Revenues: $5.4 billion (+1%) 1Q Earnings: $1.5 billion (+11%) Comments: Zocor and Singulair performed well in the quarter. Worldwide sales of Singulair were $801 million, up 9%. Worldwide Zocor sales were $1.1 billion, down 4%,… Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On